Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Amr Knoxville

Neither a doctor nor a teaching hospital

Research payments

$1,788,155

169 payments

Through program year 2025, Amr Knoxville is reported as receiving $1,788,155 in research payments, across 169 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $168,199 113
2024 Research $69,982 5
2023 Research $17,053 5
2022 Research $4,210 5
2021 Research $1,488,969 39
2020 Research $39,743 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. Valneva Austria GmbH $1,487,947 38 payments
  2. Novartis Pharmaceuticals Corporation $147,227 7 payments
  3. Boehringer Ingelheim International GmbH $102,997 114 payments
  4. AstraZeneca Pharmaceuticals LP $39,043 1 payment
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $6,800 3 payments
  6. Pfizer Inc. $2,574 5 payments
  7. Arthrex, Inc. $1,567 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $1,207,173 22 payments
  2. A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-To-Lot Consistency of Three Lots of A Live-Attenuated Chikungunya Virus Vaccine Candidate (Vla1553) in Healthy Adults Aged 18 to 45 Years $256,089 10 payments
  3. A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) $138,289 1 payment
  4. MRD/PoCP study in NFLD (12 wks) $64,407 8 payments
  5. A Phase 1 Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2 Diabetes Mellitus $39,043 1 payment
  6. Obesity Long term safety in patients with CV risk $30,272 4 payments
  7. An Open-Label, Single Arm Study to Evaluate Antibody Persistence and Long Term Safety of A Live-Attenuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $24,685 6 payments
  8. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $8,238 5 payments
  9. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $8,139 104 payments
  10. MRD PoCP study in NFLD 12 wks $6,979 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record